Skip to content
ES

Less noise. More signal.

Context · Lifespan & Healthspan · sweep Tuesday, November 17, 2026

FDA regulatory reconfiguration under MAHA influence over supplements and peptides

The FDA and HHS are creating ad hoc regulatory categories for wellness compounds (NAC, unapproved peptides) under pressure from Kennedy's MAHA movement, substituting evidence evaluation with political accommodation. This matters because it redefines the legal perimeter of supplements and compounded medicine in the US, with direct consequences for the longevity market and the agency's regulatory credibility.

Title, thesis and gravity assessment written by an AI model, without prior human review.

Gravity58/100 · Context
Why this gravity
STAT+ reporta tres movimientos regulatorios de FDA/HHS bajo influencia MAHA: permitir compounding de péptidos no aprobados, crear categoría para el suplemento NAC y finalizar guía sobre software de fármacos, redefiniendo el perímetro legal de suplementos y medicina compuesta en EEUU. Son ajustes de guía y categorías ad hoc, sin cifras, benchmark ni reforma estatutaria amplia, y con evidencia de una sola fuente (STAT), lo que limita la señal a contexto sectorial más que a evento tectónico.
— Assessment by the Semantic Gravity Engine
Coverage
1 feed · 1 independent publisher group (a single publisher group)
Cross verticals
Lifespan & Healthspan, Geopolitics
Gravity vs. the previous edition
−2 (60 → 58)

coverage, not accuracy

First detected Mon, Nov 16 · 2 days trackedGravity evolution
Lead source
STAT+: HHS moves to allow compounding of some unapproved peptides · STAT News / Margaret Manto
Actors: FDA · HHS · Robert F. Kennedy Jr. · MAHA
Timeline · Madrid time
  1. 15:17
  2. 17:35
  3. 19:54
ShareWhatsApp
Related stories